Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
CAR-expressing T cells demonstrate impressive response rates hematological malignancies, but mediate limited anti-tumor efficacy in solid tumors. The T cell exhaustion-mediated dysfunction is an important barrier to progress, which raises the prospect that engineering exhaustion-resistant CAR-T cells could improve clinical outcomes.
Benefiting from advanced technology and years of experience, Creative Biolabs is gaining even greater success in developing innovative next-generation CAR-T products. We are proud to present a model CAR system - c-Jun overexpression-mediated T cell resistant to exhaustion, which is most likely to exert maximum anti-tumor efficacy in solid tumors, thereby addressing a major obstacle to this emerging therapeutic class.
c-Jun CAR Design
A theoretical basis for exhaustion in human T cells expressing CAR receptors is that because of an imbalance between activating and immunoregulatory AP-1-IRF complexes by inducing overexpression of c-Jun - an AP-1 family transcription factor associated with productive T cell activation. A paper published in the journal Nature in December 2019 confirmed this hypothesis.
To study the biology of exhaustion in T cells, the authors used a model system that induces fatigue by expressing the tone signal CAR. They designed a bicistronic CAR vector incorporating a JUN-P2A region, 14g2a-E101K scFv, which has shown enhanced amplification potential, enhanced functionality, reduced terminal differentiation and improvement antitumor efficacy in multiple in vivo models.
One-stop CAR Development Services
With state-of-art CAR development platforms and advanced technologies, Creative Biolabs is capable of offering CAR-T-cell development services. For the regular or custom CAR backbone construction, please refer to our related services: CAR Design & Construction. To further assess your c-Jun CAR biological efficacy (e.g., cytokine production, tumor killing, and CAR-T cell proliferation), our scientists can also provide comprehensive downstream services to complete your whole research. Please click CAR Cell In Vitro Assay Service, CAR-T Preclinical In Vivo Assay for more details.
Fig.1 One-stop CAR-T therapy development process.
Features of our Services
For more detailed information, please feel free to contact us or directly sent us an inquiry.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
